STOCKHOLM, SWEDEN – September 8, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company's CFO and Deputy CEO, Fredrik Järrsten, has decided to resign from his position. He will remain in his current role until a successor has been appointed, but no later than 7 March 2021.
Fredrik Järrsten has been CFO of Karolinska Development since 2017 and Deputy CEO since 2019. He leaves the position at his own request to take up another senior role in the life science industry but will be at the company's continued disposal during the notice period to ensure a smooth transition process.
"We would like to extend our sincere gratitude and appreciation to Fredrik Järrsten for his significant efforts and great commitment during the time in Karolinska Development's management team and wish him all the best for the future," says Viktor Drvota, CEO of Karolinska Development.
Karolinska Development will immediately initiate a process to recruit a new CFO.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: firstname.lastname@example.org
Fredrik Järrsten, CFO and deputy CEO, Karolinska Development AB
Phone: +46 70 496 46 28, e-mail: email@example.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com
This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 7:30 CET on 8 September 2020.